^
Association details:
| Biomarker: | ALK translocation |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Excerpt:
Summary of recommendations...There is anecdotal evidence of activity of several molecular targeted agents: Crizotinib in inflammatory myofibroblastic tumours associated with ALK translocations [IV, C].
DOI:
10.1093/annonc/mdy310
